12 results on '"Shveta Gupta"'
Search Results
2. Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution
- Author
-
James E. Stein, Larry Wang, Shveta Gupta, Leo Mascarenhas, Kasper S. Wang, Rajkumar Venkatramani, and Shengmei Zhou
- Subjects
Hepatoblastoma ,Male ,Pathology ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Histology ,Adolescent ,medicine.medical_treatment ,Glypican 3 ,Article ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Immunophenotyping ,Biomarkers, Tumor ,medicine ,Humans ,Child ,Retrospective Studies ,Chemotherapy ,Lung ,business.industry ,Liver Neoplasms ,General Medicine ,medicine.disease ,digestive system diseases ,medicine.anatomical_structure ,Child, Preschool ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,030211 gastroenterology & hepatology ,business ,Immunostaining - Abstract
Aims The primary aim of this study is to characterize hepatocellular malignant neoplasm, NOS (HEMNOS), a new provisional entity describing a subset of paediatric hepatocellular tumours, which have histological features of neither typical hepatoblastoma (HB) nor hepatocellular carcinoma (HCC). Methods and results The clinicopathological features of 11 patients with HEMNOS were analysed retrospectively. The median age and serum alpha-fetoprotein level at diagnosis was 7 years and 182 000 ng/ml, respectively. Ten patients presented with pretreatment extent of disease (PRETEXT) stages III/IV multifocal tumours, eight with major vascular involvement, three with lung metastases and three with extrahepatic extension. The original pathology diagnoses were: HB in seven patients, HCC in two and HEMNOS in two. Our pathology review of pre-chemotherapy specimens showed that six tumours had equivocal/overlapping histological features of HB and HCC, four had predominant HB histology along with focal HCC-like histology and one had HB histology. Seven of nine post-chemotherapy resection specimens showed predominant HCC-like histology. Beta-catenin, glypican 3 and spalt-like transcription factor 4 immunostaining showed that all the tumours had a mixed HB/HCC immunophenotype. Telomerase reverse transcriptase immunostaining showed nuclear staining in nine of the 11 tumours. All patients received chemotherapy and achieved gross total primary tumour resection. Nine of the 11 patients were treated with established HB chemotherapy regimens. After a median follow-up of 6.1 years (range: 1.2–11.8 years), all patients were in remission. Conclusions HEMNOS is a subtype of HB with focal HCC-like histology, a high-risk clinical profile but favourable outcome following chemotherapy and complete tumour resection.
- Published
- 2017
3. International Survey for Strategies Used for Oral Anticoagulation Reversal in Children
- Author
-
Ayesha Zia, Ravindra Sarode, and Shveta Gupta
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.operation ,business.industry ,Immunology ,Pharmacist ,Idarucizumab ,Cell Biology ,Hematology ,Off-label use ,Octapharma ,Institutional review board ,Biochemistry ,Dabigatran ,Emergency medicine ,medicine ,Hemostatic function ,business ,medicine.drug ,Partial thromboplastin time - Abstract
Background: Vitamin K antagonists (VKA) have been the main stay of oral anticoagulation (OAC) in pediatrics. However, VKA have multiple challenges. The pharmacological properties of direct oral anticoagulants (DOACs) suggest that they may have advantages particularly for children. The off-label use of DOACs is however on the rise within the pediatric population. The increasingly broad and varied use of DOACs, lack of published clinical guidance, and limited data on reversal strategies have created the imperative to identify strategies for OAC reversal in pediatrics. We conducted an online survey for strategies used for oral anticoagulants reversal in pediatrics. Study Design: Institutional review board approval was obtained and an online survey was developed using the RedCap. The survey was electronically distributed by International Society of Hemostasis and Thrombosis (ISTH) to its Pediatric/Neonatal Thrombosis and Hemostasis Subcommittee group members. The survey questions asked approach to common hypothetical clinical scenarios for OAC reversal.The data were analysed descriptively. Results: There were 76 respondents, majority from academic free-standing Children'sHospitals. Seventy-two percent reported having a hemostasis-thrombosis/anticoagulation service but only 29 % have a dedicated anticoagulation pharmacist. Approximately 40% do not have a formal protocol in place for VKA reversal. For a supra-therapeutic INR (INR > 5) in a non-bleeding patient, 95% opted to manage by omitting the next dose of VKA while 18 % opted to give oral vitamin K alone or comitantly. For clinically relevant non-major bleeding, majority indicated using Vitamin K; oral (51%) or IV (37). For major bleeding on VKA, majority use either a combination of 4F-PCC and IV Vitamin K or plasma and IV Vitamin K (44/76 and 26/76 respectively). The presence of bleeding seemed to be the major driver for the choice of route (enteral versus parenteral) for Vitamin K for VKA reversal. Thirty-six of the 76 respondents indicated using DOACs; 94% used FXa inhibitors and 1/3 use dabigatran in their clinical practice. For non-urgent DOAC reversal, 97% indicated omitting the next dose. For non-major bleeding on DOAC, majority (29/36) indicated omitting the next dose/doses, some chose 4F-PCC (8/36) and only a few indicated use of specific reversal agents (3/36 and 1/36 for Dabigatran and Andexanet respectively). For major bleeding while on DOACs, the use of specific reversal agents (11/35, 6/35 for Andexanet and idarucizumab respectively) followed by 4F-PCC (9/35) was the major intervention indicated. Dilute thrombin time and partial thromboplastin time were the most commonly utilized tests to measure residual dabigatran activity. For Factor Xa inhibitors routine heparin assay rather than DOAC calibrated anti-Xa activity is utilized by most of the responders to assess presence of the plasma drug activity. Conclusion: Practices for oral anticoagulants reversal vary substantially in the pediatric population. Plasma is still used for urgent VKA reversal in many pediatric centers. The off-label use of DOACs in children is on the rise. Our results highlight the need for further studies to standardize OAC reversal in children. Disclosures Gupta: Novo Nordisk: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda-Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CSL Behring: Research Funding; Novartis: Honoraria, Speakers Bureau; Octapharma: Honoraria, Membership on an entity's Board of Directors or advisory committees. Sarode:Portola: Honoraria; Octaphrarma: Consultancy; CSL Behring: Consultancy; Siemens: Research Funding. OffLabel Disclosure: The pharmacological properties of direct oral anticoagulants (DOACs) suggest that they may have advantages particularly for children. They are currently not approved in children. The off-label use of DOACs is however on the rise within the pediatric population.
- Published
- 2019
4. Emicizumab-Kxwh for Previously Untreated Patients with Haemophilia: The Conversation Begins
- Author
-
Shveta Gupta, Tiffany Lin Lucas, Fernando F. Corrales-Medina, and Joanna A. Davis
- Subjects
Emicizumab ,Pediatrics ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,education ,Immunology ,Cell Biology ,Hematology ,Haemophilia ,medicine.disease ,Biochemistry ,Thrombosis ,Hemophilias ,medicine ,Combined Modality Therapy ,Conversation ,business ,health care economics and organizations ,media_common - Abstract
Introduction: With the Federal Drug and Administration approval of the use of emicizumab from birth to adulthood, clinicians will now grapple with when to choose and offer emicizumab for routine prophylaxis, especially in previously untreated patients (PUPs). Given the overall limited real-world reported data and experience using emicizumab in PUPs, we created and administered a survey to medical providers in the United States who care for paediatric patients with haemophilia to investigate real-world practice strategies and treatment selection for PUPs. Methods: After review and endorsement by the Haemostasis and Thrombosis Research Society (HTRS), the survey was electronically distributed by e-mail to all providers included in the HTRS core member list. The survey was also sent to those providers included in a list of Haemophilia Treatment Centre (HTC) physicians (with duplicate emails reconciled). Providers needed to self-identify as ones that treat pediatric patients to be included. The survey was developed as a tiered survey with questions presented to each recipient based on their prior responses. Results: Seventy-seven completed surveys were included and analysed. All participants were active providers at a comprehensive HTC and the majority (93.4%) were practicing at an academically affiliated site. In terms of characteristics of those that answered the survey, forty-eight percent of responders reported that 1-20% of their patients had expressed interest in emicizumab. 46% of participants (34/74) reported that they would personally consider emicizumab as their prophylaxis recommendation for the majority (>50%) of their hemophilia A patients without inhibitors. 57% (44/76) reported that 1-10% of their non-inhibitor hemophilia A patients were already prescribed emicizumab prophylaxis. Each participant was then asked about his or her consideration of emicizumab as prophylaxis therapy for a 2 month old PUP. Just over the majority were unsure or said no to this consideration (51.3%) and their concerns were lack of information on safety and efficacy in this young age group and increased risk for inhibitor development. If the 2 month old PUP had a high risk of inhibitor, the majority of providers who initially were hesitant to start emicizumab prophylaxis would remain so. Of note, those providers went on to be asked if the patient had gone on to complete 50 exposure days without inhibitor development, they would then become more likely to initiate emicizumab prophylaxis therapy. Use of concurrent factor replacement was posed to all participants and there were varied responses. Discussion: Overall, our results reflect a widespread practice variation and a not yet well-standardized or defined approach for the use of emicizumab in PUPs with haemophilia A. In this survey, patient preference and individual bleeding risk were the top reasons for which a provider would consider using switching to emicizumab prophylaxis in both severe and mild/moderate haemophilia A patients. This pattern of practice reflects the current era of individualized medicine. Overall, our findings reinforce the need for more studies to investigate the outcomes of a combined treatment approach with FVIII concentrates and emicizumab focusing in the potential benefit of this approach in decreasing the risk for inhibitor development PUPs. Clinicians also feel the need for further data to help clarifying the safety of emicizumab in this population. Figure Disclosures Gupta: Novartis: Honoraria, Speakers Bureau; CSL Behring: Research Funding; Novo Nordisk: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Octapharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda-Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Davis:Sanofi: Membership on an entity's Board of Directors or advisory committees; Kedrion: Membership on an entity's Board of Directors or advisory committees; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda Shire: Consultancy; Spark Therapeutics: Consultancy. Corrales-Medina:Kedrion: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda-Shire: Membership on an entity's Board of Directors or advisory committees, Research Funding; Octapharma: Membership on an entity's Board of Directors or advisory committees.
- Published
- 2019
5. Off-Label Utilization Trend for Recombinant Factor VIIa in Children's Hospitals in the United States
- Author
-
Shveta Gupta, Sarah H. O'Brien, and Joseph Stanek
- Subjects
medicine.medical_specialty ,biology ,business.operation ,business.industry ,Mortality rate ,Immunology ,Cell Biology ,Hematology ,Off-label use ,Octapharma ,Biochemistry ,Hemophilias ,Recombinant factor VIIa ,Severity of illness ,Emergency medicine ,biology.protein ,Medicine ,Diagnosis code ,business ,Cohort study - Abstract
Background: Recombinant FVIIa (rFVIIa) was approved by the Food and Drug Administration (FDA) as a hemostatic agent in 1999 for the treatment of patients with hemophilia and inhibitory antibodies against either factor VIII or IX and subsequently approved for use in patients with congenital factor VII deficiency and Glanzmann Thrombasthenia refractory to platelet transfusions in 2005 and 2014 respectively. These are rare disorders and the use of rFVIIa in these conditions has been found to be effective and safe. Despite this very narrow indication for usage, rFVIIa is being used for a diverse range of off-label indications. Along with uncertainty regarding clinical efficacy, available data suggests that the risk of thromboembolic events is increased when rFVIIa is used in off-label settings. Studies on the off-label use of rFVIIa in children are limited to a few large case series. In a retrospective multicenter cohort study utilizing the Pediatric Health Information System (PHIS) administrative database, Witmer et al demonstrated a 10-fold increase in the annual rate of off-label admissions from 2000 to 2007. The mortality rate in the off-label group was 34% and thrombotic events occurred in 11% of the off-label admissions. We conducted a follow up study to characterize the evolution of the off-label use of rFVIIa in children. Objective: To describe current trends of off-label utilization and adverse effects of rFVIIa in children. Study design: A retrospective multicenter cohort study utilizing the PHIS administrative database was conducted. The PHIS dataset includes 51 children's hospitals in the United States and is representative of tertiary care centers in the nation. In patients, 18 years of age or younger who received rFVIIa between 2012-2018 were included. A label admission was defined as an admission with an International Classification of Diseases (ICD-9 and ICD-10) diagnostic code for hemophilia, Factor VII deficiency or Glanzmann thrombaesthenia; admissions without these codes were classified as off-label. Data were analyzed descriptively. Results: There were 7,738 number of admissions, representing 6,493 unique individual subjects. A total of 78.3 % of the admissions were off-label. The rate of off-label use was stable at approximately 80% of the admissions from 2012-18. The most frequent admitting services for the off-label admissions included cardiology (29.8%), cardiovascular/thoracic surgery (15.7%), critical care (15.0%), neonatal-perinatal medicine (8.7%), and hematology/oncology (6.1%). Over half (54.6%) of off-label administration occurred in children younger than 1 year old. Among the off-label admissions 57 % were male and the median days of use of rFVIIa was 1 day. The mortality rate in the off-label group was 22.3 %. Thrombotic events occurred in 11.4% of the off-label admissions. Among the off-label admissions with thrombotic events, the most common admitting services were cardiology (35.0%) and critical care (21.2%). Conclusion: We have demonstrated that on a per admission basis the predominant use of rFVIIa is off-label. Thrombotic events are common. Although the mortality rate in the pediatric patients who received off-label rFVIIa is high; its lower when compared with the previous review. This may likely reflect, in part, the severity of illness in this patient group. In the absence of clearly supportive data demonstrating safety and efficacy, restraint should be exercised with careful consideration of risk versus benefit for use of rFVIIa in off-label settings. Disclosures Gupta: Novo Nordisk: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Octapharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; CSL Behring: Research Funding; Takeda-Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. O'Brien:Pfizer: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding. OffLabel Disclosure: Recombinant FVIIa (rFVIIa) was approved by the Food and Drug Administration (FDA) as a hemostatic agent in 1999 for the treatment of patients with hemophilia and inhibitory antibodies against either factor VIII or IX and subsequently approved for use in patients with congenital factor VII deficiency and Glanzmann Thrombasthenia refractory to platelet transfusions in 2005 and 2014 respectively. These are rare disorders and the use of rFVIIa in these conditions has been found to be effective and safe. Despite this very narrow indication for usage, rFVIIa is being used for a diverse range of off-label indications.
- Published
- 2019
6. In vitro Neurogenesis from Neural Progenitor Cells Isolated from the Hippocampus Region of the Brain of Adult Rats Exposed to Ethanol during Early Development through Their Alcohol-Drinking Mothers
- Author
-
Mohammed Younus, Yin Jiang, Shveta Gupta, Ashok K. Singh, and Mohammed Ramzan
- Subjects
medicine.medical_specialty ,Liquid diet ,Normal diet ,Antimetabolites ,Corticotropin-Releasing Hormone ,Cell Count ,Electrophoretic Mobility Shift Assay ,Acetaldehyde ,Hippocampal formation ,Biology ,Transfection ,Hippocampus ,gamma-Aminobutyric acid ,Rats, Sprague-Dawley ,Pregnancy ,Internal medicine ,medicine ,Animals ,Hippocampus (mythology) ,Calcium Signaling ,Cell Proliferation ,Neurons ,Ethanol ,Reverse Transcriptase Polymerase Chain Reaction ,Stem Cells ,Neurogenesis ,Glutamate receptor ,Central Nervous System Depressants ,Cell Differentiation ,General Medicine ,Synapsins ,Neural stem cell ,Rats ,Endocrinology ,Bromodeoxyuridine ,Fetal Alcohol Spectrum Disorders ,Synapses ,RNA ,Female ,Neuroscience ,medicine.drug - Abstract
AIMS This study was aimed to determine whether ethanol exposure during early development altered neurogenesis in the brain of adult rats. METHODS Pregnant rats were given either ethanol-mixed or mannose-mixed (for control) rodent liquid diet ad libitum. Ethanol drinking continued during pregnancy and nursing. After weaning, the pups (AC(o): pups from control mothers, AE(o): pups from ethanol exposed mothers) received normal diet and water ad libitum for 11 weeks. Then the rats were anesthetized, their brains were collected and the hippocampal samples were processed for isolation of neural progenitor cells (NPCs). AC(o) NPCs and AE(o) NPCs were sequentially grown in media containing different growth factors that induced proliferation and differentiation. RESULTS AND CONCLUSIONS Neuronal maturation was significantly delayed in ethanol-exposed rats. AC(o) NPCs, up to day 7 of culture, exhibited high beta-catenin-probe binding, an increase in Ca(2+) when exposed to gamma-amino butyric acid (GABA) and lack of response to glutamate (Glu) exposure. beta-Catenin-probe binding and the stimulatory effects of GABA declined thereafter. AC(o) NPCs, at culture day 29, exhibited high beta-catenin-probe binding, lack of response to GABA and elevated Glu-induced increase in Ca(2+i). Cultures of AE(o) NPCs showed an amplified stimulatory effects of GABA, attenuated stimulatory effects of Glu and attenuated the delayed (culture day 29) increase in the expression of Wnt proteins and beta-catenin-probe binding. This suggests a significant alteration in neurogenesis and synapse formation in adult rats exposed to ethanol at early development through their alcohol-drinking mothers.
- Published
- 2009
7. Oxidative stress and protein oxidation in the brain of water drinking and alcohol drinking rats administered the HIV envelope protein, gp120
- Author
-
Shveta Gupta, Ashok K. Singh, and Yin Jiang
- Subjects
medicine.medical_specialty ,Ethanol ,Protein Carbonylation ,Central nervous system ,Alcohol ,medicine.disease_cause ,Protein oxidation ,Biochemistry ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,medicine.anatomical_structure ,Endocrinology ,chemistry ,Apoptosis ,Internal medicine ,medicine ,Hippocampus (mythology) ,Oxidative stress - Abstract
J. Neurochem. (2008) 104, 1478–1493. Abstract Possible roles of oxidative stress and protein oxidation on alcohol-induced augmentation of cerebral neuropathy in gp120 administered alcohol preferring rats drinking either pure water (W rats) or a free-choice ethanol and water (E rats) for 90 days. This study showed that peripherally administered gp120 accumulated into the brain, liver, and RBCs samples from water drinking – gp120 administered rats (Wg rats) and ethanol drinking – gp120 administered rats (Eg rats), although gp120 levels in samples from Eg rats were significantly greater than the levels in samples from Wg rats. The brain samples from ethanol drinking-saline administered (EC) and Wg rats exhibited comparable levels of free radicals that were significantly lower than the levels in Eg rats. Peroxiredoxin-I (PrxI) activity in the brain samples exhibited the following pattern: Wg ≫ ≫ WC ≫ EC > Eg. Total protein-carbonyl and carbonylated hippocampal cholinergic neurostimulating peptide precursor protein levels, but not N-acetylaspartate or N-acetyl aspartylglutamate or total protein-thiol levels, paralleled the free radical levels in the brain of all four groups. This suggests PrxI inhibition may be more sensitive indicator of oxidative stress than measuring free radicals or metabolites. As PrxI oxidation in WC, Wg, and EC rats was reversible, while PrxI oxidation in Eg rats was not, we suggest that alcohol drinking and gp120 together hyperoxidized and inactivated PrxI that suppressed free radical neutralization in the brain of Eg rats. In conclusion, chronic alcohol drinking, by carbonylating and hyperoxidizing free radical neutralization proteins, augmented the gp120-induced oxidative stress that may be associated with an increase in severity of the brain neuropathy.
- Published
- 2007
8. Herbal Mixtures Consisting of Puerarin and Either Polyenylphosphatidylcholine or Curcumin Provide Comprehensive Protection Against Alcohol-Related Disorders in P Rats Receiving Free Choice Water and 15% Ethanol in Pure Water
- Author
-
Shveta Gupta, Ashok K. Singh, Yin Jiang, and Elhabib Benlhabib
- Subjects
Curcumin ,Interleukin-1beta ,Medicine (miscellaneous) ,Apoptosis ,Alcohol ,Acetaldehyde ,Pharmacology ,Monocytes ,law.invention ,chemistry.chemical_compound ,law ,Puerarin ,Animals ,Medicine ,RNA, Messenger ,Adverse effect ,Inflammation ,Nutrition and Dietetics ,Ethanol ,Hepatitis, Alcoholic ,Tumor Necrosis Factor-alpha ,business.industry ,Electroencephalography ,Isoflavones ,Rats ,Pleural Effusion ,Alcoholism ,Liver ,Matrix Metalloproteinase 9 ,chemistry ,Phosphatidylcholines ,Female ,Phytotherapy ,business ,Alcohol-Related Disorders - Abstract
Chronic alcohol drinking has been associated with the development of a number of abnormalities, including neuron-behavioral disorders, liver, pancreas, and heart-related diseases and inflammation and immune disorders. Because diverse mechanisms are involved in the development of these disorders, the commonly used receptor- or enzyme-specific drugs do not provide comprehensive protection against the adverse effects of alcoholism. This study describes possible therapeutic potency of puerarin (PU) from kudzu root, polyenylphosphatidylcholine from soy (SPCh), and curcumin (CU) from turmeric against alcohol's addiction-related and inflammatory-related abnormalities in alcohol-preferring P rats receiving free choice water and 15% ethanol in water. P-rats were fed once daily either the vehicle (for control) or different doses of PU, SPCh, CU, PU + SPCh, or PU + CU. The rats were divided in two groups: one received water alone, and the other free choice water and ethanol. Four rats from each group were fitted with electroencephalogram (EEG) electrodes for EEG recording. After 70 days of alcohol drinking, alcohol was withdrawn for 2 weeks, and the withdrawal symptoms were assessed. This study showed that alcohol drinking for 70 days (1) caused liver inflammation characterized by elevated tumor necrosis factor-alpha, interleukin-1beta, and matrix metalloproteinase-9 expression and (2) dysregulated lipopolysaccharide (LPS)-induced pleurisy. Alcohol withdrawal after 70 days of drinking generated severe withdrawal symptoms including seizure-type EEG activity. PU suppressed the addiction-mediated abnormalities but did not affect the inflammation-related abnormalities, while SPCh or CU suppressed only the inflammation-related abnormalities in alcohol-drinking rats subjected to LPS-induced pleurisy. A combination of PU with SPCh or CU suppressed both the addiction-related and inflammation-related abnormalities of alcohol drinking. Therefore, a mixture consisting of PU and either SPCh or CU may provide alternative therapy for alcohol-related disorders.
- Published
- 2007
9. Thromboelastographic Characterization of the Activated Clotting System in Children with Sickle Cell Trait or Sickle Cell Disease
- Author
-
Guy Young, Roxana Carmona, Jemily Malvar, and Shveta Gupta
- Subjects
Male ,medicine.medical_treatment ,Pilot Projects ,030204 cardiovascular system & hematology ,Fibrinogen ,Biochemistry ,Gastroenterology ,0302 clinical medicine ,hemic and lymphatic diseases ,Thrombophilia ,Platelet ,Child ,education.field_of_study ,medicine.diagnostic_test ,Chemistry ,Thrombin ,Hematology ,Thrombelastography ,Female ,medicine.drug ,Adult ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Adolescent ,Antithrombin III ,Immunology ,Population ,Sickle Cell Trait ,Fibrin Fibrinogen Degradation Products ,Young Adult ,03 medical and health sciences ,Internal medicine ,Fibrinolysis ,D-dimer ,medicine ,Humans ,education ,Blood Coagulation ,Platelet-poor plasma ,Sickle cell trait ,Hemoglobin SC Disease ,business.industry ,Cell Biology ,medicine.disease ,Thromboelastography ,business ,Peptide Hydrolases ,030215 immunology - Abstract
Background: Recent epidemiological evidence suggests sickle cell disease (SCD) and sickle cell trait (SCT) are risk factors for venous thromboembolism. The increased in vivo markers of thrombin generation support the notion that such patients are in a chronic hypercoagulable state. In an attempt to better understand the underlying mechanism, global hemostatic assays including thrombin generation assay (TGA) and thromboelastography (TEG) have been utilized by several groups, with inconsistent results either due to small sample size or technical differences. As opposed to the bleeding disorders, the traditional methods of TEG are not sensitive to hypercoagulability. Our group developed modified methods that prolonged the baseline TEG parameters to enhance this sensitivity. These altered TEG profiles were shown to be significantly shortened by increasing concentrations of thrombin in vitro. Objectives: Global hemostatic characterization of children with SCD or SCT by using TGA and modified TEG methods. Materials and methods: In this pilot study, we obtained hemostatic data including complete blood count with differential, reticulocyte count, fibrinogen, D-dimer, thrombin antithrombin complex and prothrombin fragment 1.2 on specimens from subjects with SCD in their usual state of health, subjects with SCT and healthy controls (NC). In addition global hemostatic assays including standard and modified thromboelastography methods as well as thrombin generation assays were performed. Results: Thirty-nine African-American subjects were recruited: 12 NC, 14 SCT and 13 SCD. The median ages for the groups were 12 (Range: 5-39), 19 (Range: 2-40) and 8 (Range: 2-14) years for NC, SCT, and SCD, respectively. Females represented 58% of the NC, 57% of the SCT subjects and 38% of the SCD subjects. In vivo markers of thrombin generation and activation of fibrinolysis including D-dimer and thrombin-antithrombin complexes were higher in SCD subjects as compared to SCT and NC (p=0.001; p=0.05 respectively). Reaction (R) time, and Kinetic (K) time with modified TEG methods was significantly shorter in SCD when compared to SCT and NC (p=0.014, p=0.038) respectively. Angle (alpha) and maximum amplitude (MA) did not show any significant differences between the groups. TGA profiles did not show any difference between the three groups either. Conclusion: The in vivo use of modified thromboelastography methods is able to detect the hypercoagulability known to occur in the sickle cell disease population but a larger sickle cell trait cohort needs to be studied to determine if this group also has hypercoagulability. Importantly, this study, the first to evaluate both TEG and TGA assays in SCD or SCT population demonstrates the importance of using whole blood to differentiate these groups as the TEG assay demonstrated differences the TGA could not detect. As SCD and SCT subjects have a highly complex physiology with not only alterations in almost all the components of the coagulation system, but also variation in the quantity and function of other blood components including white blood cells, platelets and red blood cells, TEG may prove a good tool in measuring a change in the activity of the coagulation system rather than a single baseline measurement. Our results support the need for further studies using thromboelastography in SCD and SCT population in order to better understand and triage this cohort of patients for risks of thrombotic complications. Disclosures No relevant conflicts of interest to declare.
- Published
- 2016
10. Anti-inflammatory potency of nano-formulated puerarin and curcumin in rats subjected to the lipopolysaccharide-induced inflammation
- Author
-
Shveta Gupta, Ashok K. Singh, Yin Jiang, Mohamod Younus, and Mohamod Ramzan
- Subjects
Lipopolysaccharides ,Male ,Curcumin ,medicine.drug_class ,Anti-Inflammatory Agents ,Medicine (miscellaneous) ,Apoptosis ,Pharmacology ,Anti-inflammatory ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Therapeutic index ,Puerarin ,In vivo ,medicine ,Animals ,Humans ,Cytotoxicity ,Inflammation ,Neurons ,Nutrition and Dietetics ,Plant Extracts ,Isoflavones ,Bioavailability ,Rats ,Pueraria ,chemistry ,Toxicity ,Nanoparticles - Abstract
Puerarin (PU) and curcumin (CU), used commonly in traditional Chinese medicine and Ayurveda, have been shown to possess potent anti-inflammatory, anti-oxidation, and neuro-protective properties. Despite the experimental success of CU and PU in in vitro and animal models, their effectiveness has not yet been demonstrated in clinical trials, possibly because of their poor bioavailability. We hypothesized that gold nanoparticle (AuNP)-formulated PU (PU-AuNP), CU (CU-AuNP), or a combination of PU and CU (PU-CU-AuNP) were a more effective and nontoxic alternative to their bulk (nonformulated) counterparts. To test the hypothesis, bioavailability, therapeutic potency, and toxicity of bulk CU and/or PU were compared with those of their nanotized counterparts in rats subjected to the lipopolysaccharide (LPS)-induced inflammation. This study showed that a 20-mg/kg dose of bulk PU or a mixture of PU and CU did not, while their nanotized counterparts, PU-AuNP, CU-AuNP, or PU-CU-AuNP, effectively suppressed the LPS-induced inflammation and cytotoxicity in rats. In addition, PU-CU-AuNP was more potent than PU-AuNP or CU-AuNP alone. The blank AuNP (bAuNP) at ≤40 mg/kg dose did not cause any adverse effects (blood and brain lactic acid concentrations, kidney function, and neuronal apoptosis were measured) in animals. Therefore, the present observations suggest that a bi-functional AuNP loaded with CU and PU may effectively suppress the LPS-induced inflammation and cytotoxicity provided the following conditions are met: (1) The AuNP dose is at or below the no-effect dose; (2) the nanoparticles release a therapeutic dose of CU and PU in vivo; and (3) the active ingredients are released into the intracellular component of the brain.
- Published
- 2013
11. A comparative evaluation of the antibacterial efficacy of propolis, 3.0% sodium hypochlorite and 0.2% chlorhexidine gluconate against enterococcus faecalis - An in vitro study
- Author
-
Shveta Gupta, M Kundabala, ShashiRashmi Acharya, and Vasudev Ballal
- Subjects
Immunology and Microbiology (miscellaneous) ,Dentistry (miscellaneous) ,Oral Surgery ,Anatomy - Published
- 2007
12. Herbal Mixtures Consisting of Puerarin and Either Polyenylphosphatidylcholine or Curcumin Provide Comprehensive Protection Against Alcohol-Related Disorders in P Rats Receiving Free Choice Water and 15 Ethanol in Pure Water.
- Author
-
Ashok K. Singh, Yin Jiang, Elhabib Benlhabib, and Shveta Gupta
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.